



NOVEMBER 15, 2018
ERRATUM

innate pharma

CORRECTIVE INFORMATION REGARDING THE JUNE 2018 FINANCIAL STATEMENTS

- In the context of the preparation of the 2018 closing, the Company identified some areas of improvement in the methodology of calculation regarding revenue recognition according to IFRS 15.
- The impacts on the statement of income published for the six-month period ended on June 30, 2018 are summarized in the table below:

In k€	Published	Revised	Variance
Revenue from collaboration and licensing agreements	16,879	16,209	(670)
Government financing for research expenditures	6,787	6,787	-
<i>Revenue and other income</i>	<i>23,666</i>	<i>22,996</i>	<i>(670)</i>
Research and development	(33,828)	(32,322)	1,506
General and administrative	(5,576)	(5,576)	-
<i>Net operating expenses</i>	<i>(39,404)</i>	<i>(37,898)</i>	<i>1,506</i>
<i>Operating income (loss)</i>	<i>(15,738)</i>	<i>(14,902)</i>	<i>836</i>
Financial result	(787)	(550)	237
<i>Net income (loss) before tax</i>	<i>(16,524)</i>	<i>(14,452)</i>	<i>1,073</i>
Income tax expense	333	333	-
Net income (loss)	(16,191)	(15,118)	(1,073)



NOVEMBER 15, 2018
ERRATUM

innate pharma

- The impacts on the statement of financial position published for the six-month period ended on June 30, 2018 are summarized in the table below:

In k€	Published	Revised	Variance
<i>Total current assets</i>	122,642	122,642	-
Deferred tax asset	2,879	1,727	(1,152)
<i>Total non-current assets</i>	103,274	103,273	(1,152)
Total assets	225,916	224,764	(1,152)
Operational liabilities	26,235	22,934	(3,301)
Collaboration liabilities	18,309	18,309	0
Deferred revenue	21,317	38,210	16,893
<i>Total current liabilities</i>	67,216	80,808	(13,592)
Collaboration liabilities	22,321	22,118	(203)
Deferred revenue	38,450	27,643	(10,807)
Deferred tax liability	2,879	1,727	(1,152)
<i>Total non-current liabilities</i>	71,529	59,367	(12,162)
Reserves	(134,003)	(137,658)	(3,655)
Net income (loss)	(16,191)	(15,118)	(1,073)
<i>Total shareholders' equity attributable to equity holders of the Company</i>	(87,171)	(84,589)	(2,582)
Total liabilities and equity	225,916	224,764	(1,152)